

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

**(1) RESIGNATION AND CESSATION OF OFFICE OF INDEPENDENT
NON-EXECUTIVE DIRECTOR;**

**(2) NOMINATION AND PROPOSED BY-ELECTION OF INDEPENDENT
NON-EXECUTIVE DIRECTOR OF THE THIRD SESSION OF
THE BOARD; AND**

(3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The board (the “**Board**”) of directors (the “**Directors**”) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) hereby announces that, the Board resolved and approved, among others, the proposed by-election of independent non-executive Director of the third session of the Board and the proposed amendments to the articles of association of the Company (the “**Articles of Association**”).

1. RESIGNATION AND CESSATION OF OFFICE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Tsang Kwan Hung Benson has tendered a voluntary resignation from his position as an independent non-executive Director of the third session of the Board and a member of the audit committee, the remuneration and appraisal committee and the nomination committee of the Board.

Pursuant to Article 13 of the Measures for the Administration of Independent Directors of Listed Companies (《上市公司獨立董事管理辦法》) issued by the China Securities Regulatory Commission, the consecutive terms of office of an independent director shall generally not exceed six years. Mr. Tsang Kwan Hung Benson has served as an independent non-executive Director since November 28, 2019. As his tenure is approaching six years, Mr. Tsang Kwan Hung Benson has tendered his resignation to the Board.

Following the resignation of Mr. Tsang Kwan Hung Benson, he has voluntarily agreed to continue to perform his duties as an independent non-executive Director and as a member of the relevant Board committees until the proposed by-election of a new independent non-executive Director is approved by the shareholders of the Company (the “**Shareholders**”) at the upcoming extraordinary general meeting of the Company (the “**EGM**”). The resignation of Mr. Tsang Kwan Hung Benson will become effective upon the passing of the proposed by-election of a new independent non-executive Director at the EGM.

Mr. Tsang Kwan Hung Benson has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, Mr. Tsang Kwan Hung Benson does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance nor any other matter which needs to be brought to the attention of the Shareholders.

Mr. Tsang Kwan Hung Benson was diligent, conscientious, independent and impartial during his term of service. Leveraging his professional accounting expertise and extensive management experience, he made a positive contribution to the Company's compliant operations and healthy development. The Board would like to take this opportunity to express its heartfelt appreciation and gratitude to Mr. Tsang Kwan Hung Benson for his valuable contribution made to the Company during his term of service.

2. NOMINATION AND PROPOSED BY-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR OF THE THIRD SESSION OF THE BOARD

On October 28, 2025, the Board reviewed and passed a resolution in relation to nominating Prof. Tsang King Fung (“**Prof. Tsang**”) as a candidate to stand for by-election as an independent non-executive Director of the third session of the Board. Subject to being appointed at the EGM, the Board has approved to elect Prof. Tsang as a member of the audit committee, the remuneration and appraisal committee and the nomination committee of the Board. The term for Prof. Tsang's appointment as an independent non-executive Director and as a member of the audit committee, the remuneration and appraisal committee and the nomination committee of the Board shall commence upon the passing of his by-election at the EGM and shall end on the expiry of the term of the current session of the Board. The Company will enter into a service agreement with Prof. Tsang upon his appointment at the EGM. Pursuant to resolution No. 6 that was duly passed at the 2024 annual general meeting of the Company, Prof. Tsang will be entitled to an annual remuneration of RMB300,000 (before tax) upon his appointment at the EGM.

The biographical details of Prof. Tsang are as follows:

Prof. Tsang King Fung (曾勁峰), aged 47. Since 2019, he has worked for the Faculty of Law of The Chinese University of Hong Kong as an Associate Professor. From 2013 to 2019, he worked for the same institution as an Assistant Professor. From June 2011 to July 2013, he worked for the City University of Hong Kong. In 2011, he worked for The Stock Exchange of Hong Kong Limited. From 2006 to 2008, and in 2010, he practiced law at Shearman & Sterling LLP. From 2002 to 2005, he practiced law at Linklaters.

Prof. Tsang obtained his bachelor of laws (LL.B.) and postgraduate certificate in laws (PCLL) from the University of Hong Kong. He also obtained his doctor of juridical science (S.J.D.) from Georgetown University, his master of laws (LL.M.) and juris doctor (J.D.) from Columbia University, and his master of laws (LL.M.) from University College London.

Save as disclosed above, Prof. Tsang has not held any directorship in any other listed companies in the past three years. Prof. Tsang has not held any positions with the Company or its subsidiaries, and has no relationship with any Directors, supervisors, senior management or substantial Shareholders of the Company. As at the date of this announcement, Prof. Tsang does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Prof. Tsang has confirmed (i) his independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); (ii) that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, as at the date of this announcement, there is no other information relating to the proposed by-election of Prof. Tsang that shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules. The Company is not aware of any other matter which needs to be brought to the attention of the Shareholders.

The proposed by-election of independent non-executive Director of the third session of the Board is subject to approval by the Shareholders at the EGM by way of an ordinary resolution.

3. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In view of fully implementing the latest laws, regulations and normative documents, and in accordance with the Company Law of the People’s Republic of China (the “**Company Law**”), the Guidelines on the Articles of Association of Listed Companies (2025 Revision) (《上市公司章程指引(2025年修訂)》), the Guidelines of the Shenzhen Stock Exchange No. 2 for the Application of Self-Regulation Rules for Listed Companies for the Standardized Operation of Companies Listed on the ChiNext Board (《上市公司自律監管指引第2號——創業板上市公司規範運作》), the Listing Rules and other applicable regulatory provisions, on October 28, 2025, the Board resolved and approved to amend the Articles of Association (the “**Amendments to the Articles of Association**”).

The Amendments to the Articles of Association primarily include:

- (1) Uniformly changing all references to “Shareholders’ general meetings” (股東大會) to “Shareholders’ general meetings” (股東會) in accordance with the corresponding amendments to the Company Law;
- (2) Dissolving the supervisory committee of the Company (the “**Supervisory Committee**”), following which the functions and powers of the Supervisory Committee will be delegated to and exercised by the audit committee of the Board in compliance with the requirements of the aforementioned laws, regulations and regulatory rules (the “**Delegation**”);
- (3) Repealing the Rules of Procedure of the Supervisory Committee and amending other relevant rules and policies of the Company accordingly to reflect the dissolution of the Supervisory Committee and the Delegation;

- (4) Stipulating the special meeting mechanism of independent non-executive Directors;
- (5) Clarifying the duties and composition of respective Board committees;
- (6) Incorporating provisions in relation to employee representative Directors;
- (7) Improving the management mechanism for internal audits; and
- (8) Making corresponding amendments to certain provisions that are no longer applicable due to statutory and/or regulatory updates.

Save for the above, there are no material amendments to other provisions of the Articles of Association. Non-material amendments include adjustments to the numbering of provisions in the Articles of Association, cross-references to other provisions in the main text and the table of contents.

The Board has resolved to propose a resolution at the EGM to authorise the Company's legal representative and their authorized persons to handle the filing procedures in relation to the Amendments to the Articles of Association, and to make appropriate modifications to the filing documents in accordance with any comments and requirements raised by relevant regulatory authorities. The proposed Amendments to the Articles of Association are ultimately subject to the results approved by relevant regulatory authorities. Prior to the proposed Amendments to the Articles of Association becoming effective by being approved by the Shareholders at the EGM, the existing Articles of Association shall remain valid.

Save for the proposed Amendments to the Articles of Association, other provisions of the Articles of Association shall remain unchanged. The proposed Amendments to the Articles of Association are prepared in Chinese language. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

The Board is of the view that the proposed Amendments to the Articles of Association will not compromise the Board's ability to perform its usual duties and responsibilities. The Board remains committed to maintaining high standards of corporate governance and will continue to comply with the requirements set out in the Listing Rules.

The proposed Amendments to the Articles of Association are subject to approval by the Shareholders at the EGM by way of a special resolution.

GENERAL

The Board considers that the proposed by-election of independent non-executive Director of the third session of the Board and the proposed Amendments to the Articles of Association are in the interests of the Company and the Shareholders as a whole. A circular containing, among other things, details about the proposed by-election of independent non-executive Director of the third session of the Board and the proposed Amendments to the Articles of Association will be provided to the Shareholders as soon as practicable.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
October 28, 2025

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.